Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPGJ602 in Metastatic Colorectal Cancer
NCT03356158Phase 1Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CPGJ602 in metastatic colorectal cancer (mCRC) (3 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Half life and 2 more. Status: unknown.
02
Drugs
CPGJ602
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03356158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356158.